The human epidermal growth factor receptor 2 (HER2, also known as ErbB2/c-erbB2/HER2-neu), a transmembrane receptor tyrosine kinase, is overexpressed in 25–30% of breast cancers [4] and 6–50% of epithelial ovarian cancers [5]. This evidence concerns the gene ERBB2 and ovarian carcinoma.